MedPath

Firazorexton

Generic Name
Firazorexton
Clinical Trials
Related News

A Study of TAK-994 in Adults With Narcolepsy

Phase 2
Terminated
Conditions
Narcolepsy Type 1 (NT 1)
Interventions
Drug: Placebo
First Posted Date
2021-03-29
Last Posted Date
2023-12-26
Lead Sponsor
Takeda
Target Recruit Count
26
Registration Number
NCT04820842
Locations
🇺🇸

Raleigh Neurology Associates,300209729, Raleigh, North Carolina, United States

🇺🇸

Fort Wayne Neurological Center 150711262, Fort Wayne, Indiana, United States

🇫🇮

Turku University Hospital, Turku, Finland

and more 67 locations

A Study of Different Forms of TAK-994 in Healthy Adults

Phase 1
Completed
Conditions
Healthy Participants
Interventions
First Posted Date
2021-02-09
Last Posted Date
2021-04-22
Lead Sponsor
Takeda
Target Recruit Count
54
Registration Number
NCT04745767
Locations
🇺🇸

Celerion Lincoln, NE site, Lincoln, Nebraska, United States

🇺🇸

Celerion Tempe, AZ site, Tempe, Arizona, United States

A Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics (PK) of Oral TAK-994 in an Acute Sleep Phase Delay Paradigm in Healthy Male Participants

Phase 1
Completed
Conditions
Healthy Volunteers
Interventions
Drug: Placebo
First Posted Date
2020-09-16
Last Posted Date
2021-01-19
Lead Sponsor
Takeda
Target Recruit Count
19
Registration Number
NCT04551079
Locations
🇺🇸

Clinilabs Drug Development Corporation, New York, New York, United States

A Study of TAK-994 in Adults With Type 1 and Type 2 Narcolepsy

Phase 2
Terminated
Conditions
Narcolepsy Type 1 (NT1)
Narcolepsy Type 2 (NT2)
Interventions
Drug: Placebo
First Posted Date
2019-09-20
Last Posted Date
2024-10-29
Lead Sponsor
Takeda
Target Recruit Count
97
Registration Number
NCT04096560
Locations
🇺🇸

Santa Monica Clinical Trials, Los Angeles, California, United States

🇺🇸

Florida Pulmonary Research Institute, LLC, Winter Park, Florida, United States

🇺🇸

SDS Clinical Trials, Inc., Santa Ana, California, United States

and more 75 locations

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of TAK-994 in Healthy Participants

Phase 1
Completed
Conditions
Healthy Participants
Interventions
Drug: TAK-994 Placebo
First Posted Date
2019-05-01
Last Posted Date
2020-06-24
Lead Sponsor
Takeda
Target Recruit Count
121
Registration Number
NCT03933488
Locations
🇺🇸

Parexel International, Glendale, California, United States

🇺🇸

PRA Health Sciences, Salt Lake City, Utah, United States

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy